Stockpolly
Search
ALLR · NASDAQ · Biotechnology

Allarity Therapeutics (ALLR)

Develops stenoparib with DRP®-guided patient selection for advanced recurrent ovarian cancer.

$1.41
Pre-market−0.01 (−0.70%)
At close$1.42(0.00%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue000000000000
Gross profit000000000000
4543127343333
Research & development232112121211
222225221211
General & administrative222225221211
Other expenses0000100000000
Operating income−4−5−4−3−12−7−3−4−3−3−3−3
03020002000−1
Interest income000000000000
Interest expense000000000001
Other non-operating income0−30−2000−20000
Income before tax−4−2−4−2−12−7−3−2−3−3−3−3
Income tax expense000000000000
Net income from continuing operations−4−2−4−2−12−7−3−2−3−3−3−3
Net income−4−2−4−2−12−7−3−2−3−3−3−3
EPS, basic−$1,346.09−$175.51−$20,905.00−$3.40−$7.71−$1.02−$0.25−$0.15−$0.19−$0.21−$0.17−$0.21
EPS, diluted−$1,346.09−$175.51−$20,905.00−$3.40−$7.71−$1.02−$0.25−$0.15−$0.19−$0.21−$0.17−$0.21
Weighted average shares, basic410—027111615141616
Weighted average shares, diluted410—027111615141616
EBITDA−4−1−4−1−12−7−3−2−3−3−3−2
Depreciation & amortization000000000000
EBIT−4−1−4−1−12−7−3−2−3−3−3−2